Back

mr. dr. G.H. (Filip) de Vuure

mr. dr. G.H. (Filip) de Vuure

Assistant Professor - medical

Show full profile

Research Output (84)

Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment

de Graan Anne-Joy M, Teunissen Sebastiaan F, de Vos Filip Y F L, Loos Walter J, van Schaik Ron H N, de Jongh Felix E, de Vos Aad I, van Alphen Robbert J, van der Holt Bronno, Verweij Jaap, Seynaeve Caroline, Beijnen Jos H, Mathijssen Ron H J 20 Aug 2011, In: Journal of Clinical Oncology. 29 , p. 3240-6 7 p.

Choosing chemotherapy in patients with advanced urothelial cell cancer who are unfit to receive cisplatin-based chemotherapy.

de Vos FYFL, de Wit R.J. Nov 2010, In: therapeutical advances in medical oncology. 2 , p. 381-388

Histiocytic sarcoma localised in the thyroid:a case report

De Vos Filip Y F L, Gerding Martin N, Arends Jan W, Wegman Jurgen J Aug 2008, In: Annals of Hematology. 87 , p. 681-2 2 p.

A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors

Gietema J A, Hoekstra R, de Vos F Y F L, Uges D R A, van der Gaast A, Groen H J M, Loos W J, Knight R A, Carr R A, Humerickhouse R A, Eskens F A L M Aug 2006, In: Annals of Oncology. 17 , p. 1320-7 8 p.

Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity.

Broker LE, de Vos FYFL, van Groeningen C.J., Kuenen B C, Gall HE, Woo MH, Voi M, Gietema J.A., de Vries E.G.E., Giaccone G. Mar 2006, In: Clinical Cancer Research. 12

Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination.

Hoekstra R., de Vos FYFL, Eskens F.A., de Vries E.G.E., Uges D.R.A., Knight R.T., Carr R.A., Humerickhouse R.A., Verweij J, Gietema J.A. Mar 2006, In: European Journal of Cancer. p. 467-472

Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer.

Hoekstra R., de Vos FYFL, Eskens F.A., Gietema J.A., van der Gaast Ate, Groen Harry J M, Knight RA, Carr R.A., Humerickhouse R.A., Verweij J, de Vries E.G.E. Aug 2005, In: Journal of Clinical Oncology. 23 , p. 5188-5197

A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma.

de Vos FYFL, Bos AME, Schaapveld M., de Swart CA, Graaf H., van der Zee A.G., Boezen H. M., de Vries E.G.E., Willemse P.H.B. Apr 2005, In: Gynecologic Oncology. 97 , p. 60-67

A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer.

Bos A.M.E., de Vos FYFL, de Vries E.G.E., Beijnen Jos H, Rosing Hilde, Mourits M. J. E., van der Zee A.G., Gietema J.A., Willemse P.H Mar 2005, In: European Journal of Cancer. 41 , p. 539-548

Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy; cardiovascular risk factors and signs of vascular damage.

de Vos FYFL, Nuver J, Willemse P.H, van der Zee A.G., Messerschmidt J, Burgerhof J.G., de Vries E.G.E., Gietema J.A. Mar 2004, In: European Journal of Cancer. 40 , p. 696-700

Thank you for your review!

Has this information helped you?
Please tell us why, so that we can improve our website.

Working at UMC Utrecht

Contact

Emergency?

Directions

Appointments

Practical

umcutrecht.nl uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not